Capital International Investors Boosts Holdings in Qiagen N.V. $QGEN

Capital International Investors grew its stake in shares of Qiagen N.V. (NYSE:QGEN) by 14.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,323,093 shares of the company’s stock after purchasing an additional 298,339 shares during the period. Capital International Investors owned approximately 1.05% of Qiagen worth $103,793,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Qiagen by 1.9% in the third quarter. Vanguard Group Inc. now owns 9,424,809 shares of the company’s stock worth $420,401,000 after buying an additional 172,062 shares during the period. Norges Bank bought a new position in shares of Qiagen in the 2nd quarter worth approximately $158,728,000. Allspring Global Investments Holdings LLC raised its position in shares of Qiagen by 5.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,874,356 shares of the company’s stock worth $133,140,000 after acquiring an additional 141,393 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of Qiagen by 18.2% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 2,334,083 shares of the company’s stock worth $103,372,000 after acquiring an additional 360,153 shares in the last quarter. Finally, Sei Investments Co. lifted its stake in shares of Qiagen by 0.5% in the 2nd quarter. Sei Investments Co. now owns 1,812,002 shares of the company’s stock valued at $87,085,000 after purchasing an additional 8,746 shares during the period. 70.00% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. TD Cowen restated a “hold” rating on shares of Qiagen in a research report on Friday, February 6th. Deutsche Bank Aktiengesellschaft lowered Qiagen from a “buy” rating to a “hold” rating and raised their price objective for the company from $52.00 to $54.00 in a research report on Thursday, January 22nd. Robert W. Baird set a $53.00 target price on shares of Qiagen in a report on Friday, February 6th. Zacks Research downgraded shares of Qiagen from a “hold” rating to a “strong sell” rating in a research report on Monday. Finally, UBS Group set a $52.00 price target on shares of Qiagen in a research note on Monday, February 9th. Four equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Qiagen has a consensus rating of “Hold” and an average price target of $55.20.

Qiagen Stock Performance

Qiagen stock opened at $41.15 on Thursday. Qiagen N.V. has a twelve month low of $40.14 and a twelve month high of $57.81. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $8.69 billion, a P/E ratio of 20.41, a PEG ratio of 2.10 and a beta of 0.70. The stock’s 50 day moving average is $49.58 and its 200 day moving average is $48.99.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, February 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The business had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. During the same quarter in the previous year, the business earned $0.61 earnings per share. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. On average, equities research analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.